Semaglutide Weight Loss Results Week by Week: What to Actually Expect

Key takeaways:

• Weeks 1-4 are a titration period with minimal weight loss (1-2% of body weight on average)
• Noticeable appetite suppression typically begins around weeks 4-8 as the dose increases
• The STEP 1 trial showed an average of 14.9% body weight loss at 68 weeks on the 2.4 mg dose
• Individual results vary significantly based on starting weight, dose, diet, and exercise habits
• Most side effects peak during dose increases and stabilize within 2-4 weeks at each dose level

Important: This is not medical advice. The information below summarizes published clinical trial data and peer-reviewed research for educational purposes only. Always consult a qualified healthcare provider before starting any medication. See our full medical disclaimer.

---

Why a week-by-week timeline matters

Social media is full of dramatic before-and-after photos showing massive weight loss on semaglutide. What those photos rarely show is the timeline. Someone posts a 50-pound transformation with no context on whether that took 3 months or 18.

The reality is more gradual than the highlight reels suggest. Semaglutide follows a structured dose titration schedule that directly impacts when results appear. Understanding that schedule — and what the clinical trials actually measured at each phase — helps set realistic expectations.

The data below draws primarily from the STEP 1 trial (PMID: 33567185), the STEP 5 long-term trial (PMID: 35441470), and STEP 8 (PMID: 36480218).

The dose titration schedule

Before diving into week-by-week results, you need to understand how semaglutide dosing works. The FDA-approved weight management dose (Wegovy) follows a 16-week escalation:

Weeks	Dose	Purpose
Weeks 1-4	0.25 mg/week	Initial tolerance
Weeks 5-8	0.5 mg/week	Building tolerance
Weeks 9-12	1.0 mg/week	Intermediate dose
Weeks 13-16	1.7 mg/week	Approaching target
Week 17+	2.4 mg/week	Maintenance dose

This schedule exists for a reason. Starting at the full 2.4 mg dose would produce severe gastrointestinal side effects in most people. The slow ramp-up gives your body time to adjust. It also means that meaningful weight loss does not start at full speed on day one.

Weeks 1-4: The slow start (0.25 mg)

This phase is about tolerance, not transformation.

At 0.25 mg, you are on one-tenth of the target dose. Most people experience mild appetite changes and possibly some nausea. Weight loss during this period is typically minimal — research suggests an average of 1-2% of body weight over the first month (PMID: 33567185).

For someone starting at 220 pounds, that translates to roughly 2-4 pounds in the first month.

What you might notice:

• Slightly reduced appetite, especially in the first 2-3 days after injection
• Mild nausea (the most common side effect, affecting roughly 44% of participants across the STEP trials)
• Possible constipation or stomach discomfort
• The appetite suppression effect may fade before your next weekly dose

What you probably will not notice: dramatic hunger changes, significant scale movement, or loose clothing.

This is normal. The medication is working — your body is just adjusting to it.

Weeks 5-8: Appetite shifts begin (0.5 mg)

The dose doubles, and most people start feeling a real difference in appetite.

At 0.5 mg, the GLP-1 receptor activation is stronger. Gastric emptying slows more noticeably. Many people report that they feel full faster at meals, think about food less between meals, and find it easier to stop eating when satisfied rather than when the plate is empty.

Weight loss in the STEP trials averaged approximately 3-5% of body weight by week 8. For our 220-pound example, that is roughly 7-11 pounds from baseline (PMID: 33567185).

Common experiences during this phase:

• More consistent appetite suppression throughout the week
• Reduced cravings, particularly for high-calorie and high-sugar foods
• Some participants report changes in food preferences (less desire for greasy or heavy foods)
• GI side effects may increase briefly when moving from 0.25 mg to 0.5 mg, then stabilize
• Energy levels may fluctuate as your caloric intake naturally decreases

This is often when people first feel like the medication is "doing something." The first month can feel frustratingly slow. Months two and three are where the trajectory changes.

Weeks 9-16: The acceleration phase (1.0 mg to 1.7 mg)

This is where the data gets interesting.

By week 12, STEP 1 participants on the semaglutide arm had lost an average of approximately 8-10% of their body weight. By week 16, as the dose approached 2.4 mg, the average moved closer to 10-12% (PMID: 33567185).

For someone starting at 220 pounds, week 16 results average roughly 22-26 pounds lost.

Several things happen during this phase:

Appetite suppression deepens. At 1.0 mg and above, most people describe a fundamental shift in their relationship with hunger. The "food noise" — that constant background hum of thinking about what to eat next — quiets significantly. This is one of the most commonly reported experiences and one of the hardest to quantify in clinical trials.

Side effects may resurge briefly. Each dose increase can trigger a temporary return of nausea or GI symptoms. These typically last 1-2 weeks at each new dose level before stabilizing. The STEP trials showed that discontinuation due to side effects occurred in approximately 7% of participants, most commonly during the titration period (PMID: 33567185).

Weight loss becomes more linear. After the initial slow start, the rate of loss tends to stabilize at roughly 1-2 pounds per week for many people. This is consistent with a sustained caloric deficit driven by reduced appetite rather than a crash diet.

Months 4-6: Approaching the maintenance dose (2.4 mg)

Once you reach the full 2.4 mg dose (typically around week 17), you are at the therapeutic level that produced the headline results in the STEP trials.

At this stage, the STEP 1 data shows continued steady weight loss. By month 6 (approximately week 24-26), participants had lost an average of 12-15% of their starting body weight (PMID: 33567185).

The STEP 5 trial, which followed participants for 104 weeks (2 years), confirmed that weight loss continued beyond 6 months, though the rate slowed. Maximum weight loss averaged approximately 15.2% at around 60-68 weeks before plateauing (PMID: 35441470).

What months 4-6 typically look like:

• Consistent but gradually slowing rate of weight loss
• Side effects have generally stabilized — if you are going to tolerate the medication, you likely know by now
• Body composition changes become more visible (clothing fits differently, face shape changes)
• Some people hit temporary plateaus lasting 2-4 weeks before weight loss resumes
• Metabolic markers (blood sugar, cholesterol, blood pressure) often improve during this period

The long-term trajectory: What STEP 5 tells us

The STEP 5 trial is critical because it tracked outcomes for a full 2 years. Here is the weight loss curve at key milestones (PMID: 35441470):

Timepoint	Average weight loss (semaglutide 2.4 mg)
Week 20	~10-12%
Week 40	~14-15%
Week 68	~15.2% (approximate peak)
Week 104	~14.8% (maintained)

The pattern shows that most weight loss occurs in the first 40-60 weeks, followed by a plateau and maintenance phase. This is consistent with other weight loss interventions — the body reaches a new equilibrium.

The STEP 8 trial compared semaglutide directly against tirzepatide and provided additional timeline data. Semaglutide produced steady, consistent weight loss throughout the treatment period, though tirzepatide showed greater total weight loss at comparable time points (PMID: 36480218). For a detailed comparison, see our semaglutide vs tirzepatide breakdown.

What is normal vs. what is concerning

Normal experiences during semaglutide treatment:

• Slow weight loss in the first month (1-2% of body weight)
• Nausea that peaks for a few days after each dose increase then fades
• Temporary constipation or diarrhea during titration
• 2-4 week weight plateaus that resolve on their own
• Reduced interest in certain foods (especially fried, greasy, or very sweet foods)
• Feeling full after smaller portions than usual

Signs to contact your healthcare provider:

• Severe, persistent nausea or vomiting that does not improve after 2 weeks at a given dose
• Sharp abdominal pain (pancreatitis risk, though rare — reported in fewer than 1% of trial participants)
• Symptoms of gallbladder problems (pain in the upper right abdomen, especially after eating)
• Rapid, unexplained weight loss that significantly exceeds the trial averages
• Signs of dehydration from persistent GI symptoms
• Any unusual lump or swelling in the neck (thyroid monitoring is recommended)

Weight loss that is dramatically faster than the trial averages is not necessarily a good sign. If you are losing more than 1% of your body weight per week on a sustained basis, discuss this with your doctor. Rapid loss increases the risk of muscle mass depletion, gallstones, and nutritional deficiencies.

Factors that influence your personal timeline

The STEP trial averages are exactly that — averages. Individual results span a wide range. Several factors influence where you fall:

Starting weight. People with higher starting BMIs tend to lose a greater absolute number of pounds, though the percentage may be similar.

Dose tolerance. If GI side effects force you to stay at a lower dose longer, the timeline stretches. Some people never tolerate the full 2.4 mg and stabilize at 1.7 mg, which still produces meaningful results.

Diet and exercise. STEP trial participants received lifestyle counseling. Those who combined semaglutide with structured exercise and dietary changes tended to lose more weight and preserve more lean mass. The dosage calculator can help you understand standard dosing protocols.

Metabolic factors. Insulin resistance, thyroid function, medications, sleep quality, and stress all influence the rate and extent of weight loss. People with type 2 diabetes tend to lose less weight on GLP-1 medications than those without diabetes (approximately 6-7% vs 15% at similar timepoints).

Consistency. Missing doses or taking breaks disrupts the pharmacological effects. Semaglutide has a half-life of approximately one week, so a missed dose does not cause immediate rebound, but consistent weekly dosing produces the best outcomes.

The bottom line

Semaglutide produces real, significant weight loss — but it follows a predictable, gradual curve. The first month is slow. Months 2-4 are where the momentum builds. Months 4-12 are where most of the total loss accumulates. After that, the body reaches a new set point and weight stabilizes.

If you are considering semaglutide or are in the early weeks wondering whether it is working, the clinical trial data provides a useful benchmark. Comparing your progress to the STEP trial timelines is far more useful than comparing yourself to social media transformations with no context.

For a look at how semaglutide compares to other GLP-1 options, see our guide on the GLP-1 weight loss stack.

---

Sources

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
2. Garvey WT, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5). Nat Med. 2022;28(10):2083-2091. PMID: 35441470
3. Rubino DM, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity (STEP 8). JAMA. 2022;308(22):2340-2350. PMID: 36480218

---

Medical Disclaimer: The content on this page is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. See our full disclaimer.